Evidence map›Paper›PMID 30862096›Full record

ArticleViruses2019

Directed in Vitro Evolution of Therapeutic Bacteriophages: The Appelmans Protocol.

Ben H Burrowes, Ian J Molineux, Joe A Fralick

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 1 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Viruses · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Modeling the phage properties best for therapy.bioRxiv : the preprint server for biology · 2025
    Article
  19. Article
  20. Article

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ben H BurrowesDepartment of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430, USA. benburrowes@live.com.
Ian J MolineuxCenter for Infectious Disease, Department of Molecular Biosciences, The University of Texas at Austin, 1 University Station A5000, Austin, TX 78712, USA. molineux@austin.utexas.edu.ORCID 0000-0003-0184-7652
Joe A FralickDepartment of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430, USA. joe.fralick@ttuhsc.edu.
Texas Tech University · USThe University of Texas at Austin · US

Funding

NIH HHS AI48696NIH HHS GM32095
6 · The paper itself

Abstract

The 'Appelmans protocol' is used by Eastern European researchers to generate therapeutic phages with novel lytic host ranges. Phage cocktails are iteratively grown on a suite of mostly refractory bacterial isolates until the evolved cocktail can lyse the phage-resistant strains. To study this process, we developed a modified protocol using a cocktail of three

Indexed as

Phage TherapyRecombination, GeneticBacteriophagesDirected Molecular EvolutionDrug Resistance, ViralGenome, ViralHigh-Throughput Nucleotide SequencingHost SpecificityMyoviridaePseudomonas InfectionsPseudomonas Phagesantibiotic resistanceAppelmansbacteriophage evolutionbacteriophage recombinationphage therapyPseudomonas aeruginosa

Identifiers

PMID30862096
PMCPMC6466182
OpenAlexW2922498192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.